Skip to main content
. 2020 Mar 24;11:194. doi: 10.3389/fneur.2020.00194

Table 2.

Demographic and clinical characteristic of PRES patients with atypical regions.

Characteristic n
DEMOGRAPHICS AND SYMPTOMS
Sex/F 305/553 (55.2%)
Age (median, range, years) (34, 0.08–85)
Headache 282/556 (50.7%)
Altered mental status 243/556 (43.7%)
Seizures 233/556 (41.9%)
Visual disturbances 194/556 (34.9%)
Nausea/vomiting 130/556 (23.4%)
Focal neurological deficits 101/556 (18.2%)
Dizziness 38/556 (6.8%)
Gait disturbances 27/556 (4.9%)
Fever 25/556 (4.5%)
Disorientation 23/556 (4.1%)
Ataxia 20/556 (3.6%)
Dyspnea 16/556 (2.9%)
Abdominal pain 13/556 (2.3%)
Abnormal urine 12/556 (2.2%)
Others (each symptom)# ≤2%
PREDISPOSING FACTOR
Hypertension 425/556 (76.4%)
Renal diseases 152/556 (27.3%)
Immunosuppressant drugs 79/556 (14.2%)
Chemotherapy/chemoradiotherapy 59/556 (10.6%)
Autoimmune disorders 55/556 (9.9%)
Pre-eclampsia/Eclampsia 41/556 (7.4%)
Infection/sepsis/shock 32/556 (5.8%)
Steroids 24/556 (4.3%)
Metabolic disorders 15/556 (2.7%)
Miscellaneous drugs 13/556 (2.3%)
Dialysis 12/556 (2.2%)
Transfusion 11/556 (2.0%)
Endocrine disorders 7/556 (1.3%)
Surgery 6/556 (1.1%)
Others (each factor)* ≤1%
TREATMENT
Antihypertensives 358/515 (69.5%)
Antiepileptics/sedation 126/515 (24.5%)
Discontinuation/switching agents 67/515 (13.0%)
Steroid 54/515 (10.5%)
Dehydrating/diuretics 34/515 (6.6%)
Intracranial decompression 24/515 (4.7%)
Hemodialysis 23/515 (4.5%)
Immunosuppressive therapy 20/515 (3.9%)
Anti-infective treatment 16/515 (3.1%)
Others (each treatment)$ ≤2%

The main characteristics (>10%) are marked in bold.

Others (each symptom)#: involuntary movement, fatigue, behavioral changes, edema, loss of appetite, neck stiffness, diarrhea, polydipsia and weight loss, purpura, and insomnia.

Others (each factor)*: sickle cell disease, substance abuser, reduction in intracranial pressure, intoxication, contrast medium exposure, trauma, multiple system atrophy, embolus, hyperbaric oxygen therapy.

Others (each treatment)$: plasma exchange, treatment for tumor, renal angioplasty, glyceryl trinitrate infusion, and others <1%.